Imagine a life where the world you see in front of you slowly begins to go black, where your central vision is slowly erased, causing you to lose your ability to complete the simplest of daily tasks. This is the life of someone with Age-Related Macular Degeneration (AMD) and other retinal disorders. The reality is over 11 million people in the United States have some form of age-related macular degeneration — a number that is expected to double to nearly 22 million by 2050, leaving many with low vision in search of better visual aid solutions.
Eyedaptic develops innovative visual solutions, designed to help these individuals regain their independence and improve the quality of life that is often lost with AMD and other low vision disorders. President and CEO Jay Cormier will present Eyedaptic Augmented Reality (AR) visual aid’s clinical trial along with more than 300 hours of beta user data at the Ophthalmology Innovation Summit’s Innovation Showcase, at the Ritz Carlton in Chicago (OIS & ASRS) on Thursday, July 25.
Jay Cormier will discuss how Eyedaptic’s first-generation prototype device enables improved vision endpoints. This improved vision enables the user the freedom to complete everyday tasks and a return to the independence that was lost.
“We are fortunate to have this opportunity to present this important clinical data at another Ophthalmology Innovation Summit,” commented Jay Cormier. “By leveraging the power of augmented reality software within a visual aid device we have seen first-hand how this technology can improve vision. It is truly life-changing.”
Eyedaptic is a software technology company addressing unmet needs in the ophthalmic field, focused on developing and marketing visually assistive Augmented Reality (AR) devices with embedded simulated natural vision software in open market hardware platforms. For many Age-related Macular Degeneration (AMD) sufferers, the world has disappeared before their eyes. These devices are designed to offer low vision consumers a non-invasive, mobile visual aid to address retinal field of vision impairments. The Eyedaptic EYE-01 efficacy data, from the inaugural clinical trial, along with usability data from extended in-home usage reinforces improved reading acuity as well as greater success with independent activities of daily living. Learn more at eyedaptic.